Clinical trials
Recurrence trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
228 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 19 |
| 2016 | 16 |
| 2017 | 19 |
| 2018 | 12 |
| 2019 | 29 |
| 2020 | 26 |
| 2021 | 24 |
| 2022 | 28 |
| 2023 | 16 |
| 2024 | 10 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 228 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 11 |
| Chinese PLA General Hospital | 7 |
| Fudan University | 7 |
| Peking Union Medical College Hospital | 6 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 6 |
| Zhejiang University | 5 |
| Eastern Hepatobiliary Surgery Hospital | 4 |
| Henan Cancer Hospital | 4 |
| Hrain Biotechnology Co., Ltd. | 4 |
| Peking University People's Hospital | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 228 |
| Lymphoma, B-Cell | 22 |
| Carcinoma, Hepatocellular | 21 |
| Neoplasm Metastasis | 16 |
| Leukemia, Myeloid, Acute | 15 |
| Multiple Myeloma | 12 |
| Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Leukemia | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
Trials
Showing 1 to 25 of 228. Each trial links to its page on Pharma Observatory.
128 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.